GSK and the TGA have warned they are anticipating a stock shortage for the combined adult vaccine this month
GSK has written saying it is anticipating an intermittent shortage of stock for Twinrix Adult (combined hepatitis A and B vaccine, 1 mL injection pre-filled syringe) in July.
“We understand that this stock out may be distressing for those who are not covered by government programs and who may be required to vaccinate themselves for occupational reasons or because they are planning on travelling to hepatitis-affected areas,” says GSK.
“We are working to rectify the situation as soon as possible.”
The shortage is predicted to last from 14-31 July.
GSK is also currently experiencing an on-going supply constraint of Engerix-B® Adult dose (hepatitis B surface antigen recombinant (yeast) vaccine) in Australia.
“Production is now back to normal however, it will take time to re-build capacity,” says the company.
“At this stage we are unable to confirm a re-supply date.”
Shortage dates for Engerix-B 20 microgram/1mL injection syringe began on 25 November 2016, and are predicted to last until 30 January 2018.
Both Twinrix Junior and Engerix-B Paediatric continue to be available.
Supply of GSK vaccines containing hepatitis B to government programs is not impacted.